Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05921292 · ClinicalTrials.gov registry record · Early Phase 1
Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies
A Early Phase 1 study, sponsored by Omeza.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 111
- Enrollment target
NCT05921292: Completed Early Phase 1 study, sponsored by Omeza.
NCT05921292 is a Early Phase 1 study that has completed, run by Omeza. The registered enrollment target is 111 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (109% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05921292, a Early Phase 1 study, has completed, sponsored by Omeza.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is: \- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period? Patients will be treated with: * OCM™ Wound Matrix * Omeza combination therapy * Standard of Care
Primary Outcome
The proportion of subjects with a clinically significant improvement in Study Ulcer Exudate Assessments at 4 weeks compared to baseline assessment.
Interventions
- COMBINATION_PRODUCT Omeza Products Used in Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2024-05-31 |
| Phase | Early Phase 1 |
What the finished NCT05921292 record still lists
NCT05921292 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (109% higher).
The record links to 0 conditions, and to 1 intervention - of which Omeza Products Used in Combination is the first listed.
NCT05921292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05921292 about?
NCT05921292 is a clinical study titled "Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies". The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is: \- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period? Patients will be treated...
What is the current status of trial NCT05921292?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 111 participants. The study started on 2022-07-11. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT05921292?
The interventions under investigation include: Omeza Products Used in Combination (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05921292?
This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05921292's enrollment target sits among peer trials
111 166th of 2000 higher than 1,835 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI